Lonza's core profits rose 9.5% to $720.6m in H1

Its pharma biotech & nutrition segment recorded 10.8% sales growth.

Swiss biotech and pharma company Lonza saw profits climb 9.5% YoY to $720.6m (CHF520m) in H1 2019 from $658.2m (CHF475m) in 2018, an SGX filing revealed.

Its total sales went up 6.4% YoY to $4.12b (CHF2.98b) from $3.87b (CHF2.8b) in H1 2018 whilst its EBITDA rose 7.7% YoY to $1.15b (CHF828m) on the back of positive performance from its pharma biotech & nutrition segment, which reported 10.8% YoY sales growth to $2.89b (CHF2.09b).

Earnings per share edged up $9.70 (CHF7) from $8.81 (CHF6.36) in H1 2018.

On the other hand, Lonza’s specialty ingredients segment sales dipped 3.8% YoY to $1.19b (CHF859m) from $1.24b (CHF893m) in H1 2018, no thanks to the decline in sales of its microbial-control and wood protection businesses.

Lonza noted that they are expecting a recovery of the said segment’s sales in H2.

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia